Center for Clinical and Translational Sciences (CCTS)

临床和转化科学中心 (CCTS)

• 批准号: 10316843
• 负责人: DANIEL D KARP
• 金额: $ 185.96万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-04 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10316843
• 关键词: 2019-nCoV; Administrative Supplement; Adult Respiratory Distress Syndrome; Antibodies; Applications Grants; Area; Basic Science; Biological; Blinded; Blood; COVID-19; COVID-19 pandemic; COVID-19 patient; COVID-19 treatment; Cancer Center; Case Series; Cause of Death; Childhood; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Clinical and Translational Science Awards; Collaborations; Communities; Data; Deterioration; Development; Disease; Doctor of Medicine; Ebola; Economically Deprived Population; Education; Elderly; Emergency Situation; Enrollment; Environment; Epidemic; First Independent Research Support and Transition Awards; Funding; Goals; Health Sciences; Healthcare; Hispanics; Hospitals; Human; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Incidence; Individual; Influenza; Influenza A Virus, H1N1 Subtype; Informatics; Institution; Institutional Review Boards; Intubation; Knowledge; Lesbian Gay Bisexual Transgender Queer; Long Island; Lung diseases; Malignant Neoplasms; Measles; Meta-Analysis; Middle East Respiratory Syndrome; New York; New York City; Outcome; Patients; Phase; Physicians; Placebos; Plasma; Pneumococcal Pneumonia; Process; Randomized; Reporting; Research; Research Contracts; Research Methodology; Research Personnel; Research Training; Resources; Respiratory Failure; Rice; Rural; SARS-CoV-2 antibody; Safety; Saline; Science; Serum; Severe Acute Respiratory Syndrome; Site; South Texas; Spanish flu; Texas; Therapeutic; Time; Training; Translational Research; Translations; Treatment Efficacy; Universities; Workforce Development; base; biobank; blood product; clinical center; clinical data warehouse; computer science; convalescent plasma; design; effective therapy; efficacy evaluation; experience; falls; improved; influenza pneumonia; innovation; mortality risk; next generation; novel; pandemic disease; pandemic influenza; patient population; patient registry; phase II trial; placebo controlled trial; programs; respiratory; science education; skills; translational scientist; trial comparing; trial design

In the first awarded CTSA class, the Center for Clinical and Translational Sciences (CCTS) formed the first multiple-institution CTSA, with The University of Texas Health Science Center at Houston (UTHSC-H) and The University of Texas M. D. Anderson Cancer Center (UT MDACC). Since its inception the CCTS has been achieving the primary goal of the Clinical and Translational Sciences Award (CTSA) program: to accelerate research to transform healthcare and train the next generation of translational scientists. Our initial proposal was about bringing individuals and resources together, educating investigators, and building teams. In our 2011 renewal we described our Lowering-The-Barriers program, which focused on removing a large number of impediments through initiatives such as IRB reciprocity, standard research contracts and subcontracts, clinical data warehouses, patient registries, and biobanks. Our efforts have been successful and aligned with the national CTSA program. In this cycle, we bring in 3 new partner institutions to broaden and diversify our CTSA: The University of Texas Health Science Center at Tyler (northeast Texas, rural, economically disadvantaged), Rice University (with strengths in computer science, education, and team science), and The University of Texas Rio Grande Valley (south Texas, education and physician resources to help our nearby Brownsville Clinical Research Unit perform clinical trials). Together we will effect 5 strategic goals: Strategic Goal 1: To provide our investigators, staff, trainees, and scholars with the skills and knowledge necessary to advance discoveries and their translation in the new environment of clinical and translational research (Workforce Development). Strategic Goal 2: To collaborate with all of our stakeholders in a mutually beneficial way to advance translation by furthering engagement and team science (Collaboration/Engagement). Strategic Goal 3: To integrate pediatric and geriatric patients, Hispanic patients with cancer, and the LGBTQ+ community into the full spectrum of clinical and translational research (Integration). Strategic Goal 4: To advance translational science by providing novel processes, increasing efficiency, and streamlining research (Methods/Processes). Strategic Goal 5. To create and apply innovative informatics solutions to advance translational research, train the CTSA workforce, disseminate best practices, engage communities and integrate clinical and basic research data (Informatics).

在第一次授予CTSA类，临床和转化科学中心（CCTS）形成了第一个 多机构CTSA，与德克萨斯大学休斯顿健康科学中心（UTHSC-H）和 德克萨斯大学M. D.安德森癌症中心（UT MDACC）。自成立以来，CCTS一直 实现临床和转化科学奖（CTSA）计划的主要目标：加速 研究，以改变医疗保健和培养下一代的翻译科学家。我们最初的建议 是将个人和资源聚集在一起，教育调查人员，建立团队。在我们 2011年更新，我们描述了我们的降低障碍计划，该计划侧重于消除大量的 通过IRB互惠、标准研究合同和分包合同、临床研究合同等举措， 数据仓库、患者登记处和生物库。我们的努力取得了成功，并与 国家CTSA计划。在这个周期中，我们引入了3个新的合作伙伴机构，以扩大和多样化我们的 位于泰勒的德克萨斯大学健康科学中心（德克萨斯州东北部，农村，经济 弱势），莱斯大学（在计算机科学，教育和团队科学的优势）， 和德克萨斯大学格兰德河谷（德克萨斯州南部，教育和医生资源， 帮助我们附近的布朗斯维尔临床研究单位进行临床试验）。我们一起努力5 战略目标：战略目标1：为我们的研究人员，工作人员，学员和学者提供 在新的环境中推进发现及其翻译所需的技能和知识， 临床和转化研究（劳动力发展）。战略目标2：与所有人合作 我们的利益相关者以互利的方式通过进一步参与和 团队科学（协作/参与）。战略目标3：将儿科和老年科 患者，西班牙裔癌症患者和LGBTQ+社区进入全方位的临床 转化研究（translational research）。战略目标4：推进转化科学 提供新的过程，提高效率，并简化研究（方法/过程）。 战略目标5。创建和应用创新的信息学解决方案，以推进翻译 研究，培训CTSA劳动力，传播最佳实践，参与社区和整合 临床和基础研究数据（信息学）。